• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Patricia K. Donahoe, MD


  • Park JH, Tanaka Y, Arango NA, Zhang L, Benedict LA, Roh MI, Donahoe PK, Teixeira JM.Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression.Dev Biol. 2014 Feb 1;386(1):227-36.
  • Namkung J, Song JY, Jo HH, Kim MR, Lew YO, Donahoe PK, MacLaughlin DT, Kim JH.Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.J Clin Endocrinol Metab. 2012 Sep;97(9):3224-30.
  • Chang HL, Pieretti-Vanmarcke R, Nicolaou F, Li X, Wei X, MacLaughlin DT, Donahoe PK.Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.Gynecol Oncol. 2011 Jan;120(1):128-34.
  • Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, Preffer FI, Mueller PR, Teixeira J, Maclaughlin DT, Donahoe PK.Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics.Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18874-9.
  • MacLaughlin DT, Donahoe PK.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.Future Oncol. 2010 Mar;6(3):391-405. Review.
  • Papakostas TD, Pieretti-Vanmarcke R, Nicolaou F, Thanos A, Trichonas G, Koufomichali X, Anago K, Donahoe PK, Teixeira J, MacLaughlin DT, Vavvas D.Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance.Protein Expr Purif. 2010 Mar;70(1):32-8.
  • Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N, Gross KW, Vivanco MM, Wijendran V, Shioda T, Sgroi D, Donahoe PK, Maheswaran S.HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis.Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1100-5.
  • Chang HL, Senaratne TN, Zhang L, Szotek PP, Stewart E, Dombkowski D, Preffer F, Donahoe PK, Teixeira J.Uterine leiomyomas exhibit fewer stem/progenitor cell characteristics when compared with corresponding normal myometrium.Reprod Sci. 2010 Feb;17(2):158-67.
  • Lage K,Hansen NT,Karlberg EO,Eklund AC,Roque FS,Donahoe PK,Szallasi Z,Jensen TS,Brunak S.A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes.Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20870-5.
  • Fujino A,Arango NA,Zhan Y,Manganaro TF,Li X,MacLaughlin DT,Donahoe PK.Cell migration and activated PI3K/AKT-directed elongation in the developing rat Mullerian duct.Dev Biol. 2009 Jan 15;325(2):351-62.
  • Szotek PP,Chang HL,Brennand K,Fujino A,Pieretti-Vanmarcke R,Lo Celso C,Dombkowski D,Preffer F,Cohen KS,Teixeira J,Donahoe PK.Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics.Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12469-73.
  • Kantarci S,Ragge NK,Thomas NS,Robinson DO,Noonan KM,Russell MK,Donnai D,Raymond FL,Walsh CA,Donahoe PK,Pober BR.Donnai-Barrow syndrome (DBS/FOAR) in a child with a homozygous LRP2 mutation due to complete chromosome 2 paternal isodisomy.Am J Med Genet A. 2008 Jul 15;146A(14):1842-7.
  • Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J.c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.Endocrinology. 2008 Jan;149(1):108-15.
  • Kantarci S, Donahoe PK.Congenital diaphragmatic hernia (CDH) etiology as revealed by pathway genetics.Am J Med Genet C Semin Med Genet. 2007 May 15;145(2):217-26. Review.
  • Gupta V, Yeo G, Kawakubo H, Rangnekar V, Ramaswamy P, Hayashida T, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.Cancer Res. 2007 Mar 15;67(6):2747-56.
  • Szotek PP, Chang HL, Zhang L, Preffer F, Dombkowski D, Donahoe PK, Teixeira J.Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation.Stem Cells. 2007 May;25(5):1317-25.
  • Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT.Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31.
  • Arango NA, Huang TT, Fujino A, Pieretti-Vanmarcke R, Donahoe PK.Expression analysis and evolutionary conservation of the mouse germ cell-specific D6Mm5e gene.Dev Dyn. 2006 Sep;235(9):2613-9.
  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
  • Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK.Mllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mllerian duct regression.Development. 2006 Jun;133(12):2359-69.
  • Donahoe PK.Genomic approaches to surgical diseases: 21st annual Samuel Jason Mixter lecture.Arch Surg. 2006 Apr;141(4):409-13.
  • Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.Clin Cancer Res. 2006 Mar 1;12(5):1593-8.
  • Arango NA, Szotek PP, Manganaro TF, Oliva E, Donahoe PK, Teixeira J.Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium.Dev Biol. 2005 Dec 1;288(1):276-83.
  • Wang PY, Koishi K, McGeachie AB, Kimber M, Maclaughlin DT, Donahoe PK, McLennan IS.Mullerian inhibiting substance acts as a motor neuron survival factor in vitro.Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16421-5.
  • Gupta V, Carey J, Kawakubo H, Muzikansky A, Green J, Donahoe PK, MacLaughlin DT, Maheswaran S.Mullerian Inhibiting Substance suppresses tumor grown in the C3(1)T antigen transgenic mouse mammary carcinoma model.Proc Natl Acad Sci U S A. 2005 MAR 01;102(9):3219-3224.
  • Hoshiya M, Christian BP, Cromie WJ, Kim H, Zhan Y, MacLaughlin DT, Donahoe PK.Persistent Mullerian duct syndrome caused by both a 27-bp deletion and a novel splice mutation in the MIS type II receptor gene.Birth Defects Res A Clin Mol Teratol. 2003 Oct;67(10):868-74.
  • Lee MM, Misra M, Donahoe PK, MacLaughlin DT.MIS/AMH in the assessment of cryptorchidism and intersex conditions.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):91-8.
  • Dasgupta R, Schnitzer JJ, Hendren WH, Donahoe PK.Congenital adrenal hyperplasia: surgical considerations required to repair a 46,XX patient raised as a boy.J Pediatr Surg. 2003 Aug;38(8):1269-73.
  • Misra M, MacLaughlin DT, Donahoe PK, Lee MM.The role of Mllerian inhibiting substance in the evaluation of phenotypic female patients with mild degrees of virilization.J Clin Endocrinol Metab. 2003 Feb;88(2):787-92.
  • Madsusmita M, MacLaughlin DT, Donahoe PK, Lee MM.The Role of Mllerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization .Journal of Endocrinology and Metabolism. 2003 Feb;88(2).
  • Laurich VM, Trbovich AM, O'Neill FH, Houk CP, Sluss PM, Payne AH, Donahoe PK, Teixeira J.Mllerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 17alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation.Endocrinology. 2002 Sep;143(9):3351-60.
  • Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT.Highly purified mllerian inhibiting substance inhibits human ovarian cancer in vivo.Clin Cancer Res. 2002 Aug;8(8):2640-6.
  • Madsusmita M, MacLaughlin D, Donohoe P, Lee MM.Measurement of Mullerian Inhibiting Substance Facilitates Management of Boys with Microphallus and Cryptorchidism.Harrison's Principles of Internal Medicine. 2002 Aug;87:3598-3602.
  • Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT.New approaches for high-yield purification of Mllerian inhibiting substance improve its bioactivity.J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98.
  • Segev DL, Hoshiya Y, Hoshiya M, Tran TT, Carey JL, Stephen AE, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):239-44.
  • Teixeira J, Maheswaran S, Donahoe PK.Mllerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications.Endocr Rev. 2001 Oct;22(5):657-74.
  • Sriraman V, Niu E, Matias JR, Donahoe PK, MacLaughlin DT, Hardy MP, Lee MM.Mllerian inhibiting substance inhibits testosterone synthesis in adult rats.J Androl. 2001 Sep-Oct;22(5):750-8.
  • Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK.Mllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.Mol Endocrinol. 2001 Jun;15(6):946-59.
  • Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo.J Biol Chem. 2001 Jul 20;276(29):26799-806.
  • Stephen AE, Masiakos PT, Segev DL, Vacanti JP, Donahoe PK, MacLaughlin DT.Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3214-9.
  • Trbovich AM, Sluss PM, Laurich VM, O'Neill FH, MacLaughlin DT, Donahoe PK, Teixeira J.Mllerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3393-7.
  • Ukiyama E, Jancso-Radek A, Li B, Milos L, Zhang W, Phillips NB, Morikawa N, King CY, Chan G, Haqq CM, Radek JT, Poulat F, Donahoe PK, Weiss MA.SRYand architectural gene regulation: the kinetic stability of a bent protein-DNA complex can regulate its transcriptional potency.Mol Endocrinol. 2001 Mar;15(3):363-77.
  • Morikawa N, Clarke TR, Novina CD, Watanabe K, Haqq C, Weiss M, Roy AL, Donahoe PK.Human Mllerian-inhibiting substance promoter contains a functional TFII-I-binding initiator.Biol Reprod. 2000 Oct;63(4):1075-83.
  • Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S.Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.J Biol Chem. 2000 Nov 24;275(47):37101-9.
  • Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S.Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.J Biol Chem. 2000 Sep 15;275(37):28371-9.
  • Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E.Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2626-31.
  • Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK.Endogenous expression of Mllerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites.Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1624-9.
  • Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.Clin Cancer Res. 1999 Nov;5(11):3488-99.
  • Teixeira J, Kehas DJ, Antun R, Donahoe PK.Transcriptional regulation of the rat Mllerian inhibiting substance type II receptor in rodent Leydig cells.Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13831-8.
  • Teixeira J, Fynn-Thompson E, Payne AH, Donahoe PK.Mllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.Endocrinology. 1999 Oct;140(10):4732-8.
  • Lane AH, Lee MM, Fuller AF, Kehas DJ, Donahoe PK, MacLaughlin DT.Diagnostic utility of Mllerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors.Gynecol Oncol. 1999 Apr;73(1):51-5.
  • Haqq CM, Donahoe PK.Regulation of sexual dimorphism in mammals.Physiol Rev. 1998 Jan;78(1):1-33.
  • Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK.Developmental expression of a candidate mllerian inhibiting substance type II receptor.Endocrinology. 1996 Jan;137(1):160-5.